Cytokinetics Q1 EPS $(1.67) Misses $(1.64) Estimate, Sales $19.355M Beat $8.518M Estimate.
Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(1.64) by 1.83 percent. This is a 22.79 percent decrease over losses of $(1.36) per share from the
